HHS to invest in domestic production of essential medical supplies
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
Related News Articles
Headline
The Centers for Disease Control and Prevention has issued an advisory alerting health care providers, laboratory professionals and others in health care…
Headline
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active…
Headline
The AHA sent a letter June 28 to the U.S. Trade Representative responding to a proposed increase in Section 301 tariffs for goods produced in China, which…
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In the wake of tornado damage last week to a large Pfizer sterile injectables plant in North Carolina, the Food and Drug Administration July 28 posted a list…